Результаты поиска

Consultation-Based Deprescribing Service to Optimize Palliative Care for Terminal Cancer Patients.

(1) Background: A pharmacist-led deprescribing service previously developed within the Consultation-Based Palliative Care Team (CB-PCT) was implemented for terminal cancer patients. (2) Objective: To evaluate the clinical outcomes of the developed deprescribing service for terminal cancer patients in CB-PCT. (3) Methods: A retrospective analysis compared the active care (AC) group to the historical usual care (UC) group. The clinical outcomes included the deprescribing rate of preventive medications, the proportion of patients with one or more medication-related problems (MRPs) resolved upon d

Совпадение в полном тексте источника
… All statistical analyses were performed using R-software (R for Windows 4.2; The R Foundation for Statistical Computing, Vienna, Austria) and R-studio version 3.0, with a significance level of 0.05. …

Evaluation of Preventive Role of Systemically Applied Erythropoietin after Tooth Extraction in a Bisphosphonate-Induced MRONJ Model.

Background and Objectives: In this experimental study, the prophylactic effect of systemically administered erythropoietin (EPO) in medication-related osteonecrosis of the jaw (MRONJ) was evaluated. Materials and Methods: The osteonecrosis model was established using 36 Sprague Dawley rats. EPO was systemically applied before and/or after tooth extraction. Groups were formed based on the application time. All samples were evaluated histologically, histomorphometrically, and immunohistochemically. A statistically significant difference in new bone formation was observed between the groups (p <

Совпадение в полном тексте источника
… The week after the last injection, 80–100 mg/kg ketamine hydrochloride (Ketasol ® , Richterpharma, Wels, Austria) and 10 mg/kg 2% xylazine hydrochloride (Rompun ® , Bayer, Leverkusen, Germany) were administered intramuscularly under veterinary supervision as general anesthetics before tooth extraction …

Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study.

OBJECTIVES: In anticancer clinical trials, particularly open-label trials, central reviewers are recommended to evaluate progression-free survival (PFS) and objective response rate (ORR) to avoid detection bias of local investigators. However, it is not clear whether the bias has been adequately identified, or to what extent it consistently distorts the results. Therefore, the objective of this study was to evaluate the detection bias in oncological open-label trials by confirming whether local investigators overestimate the PFS and ORR compared with the findings of central reviewers. DESIGN:

Совпадение в полном тексте источника
… The ‘metafor’ package (V.3.8–1) 25 in R (V.4.0.3; R Foundation for Statistical Computing, Vienna, Austria) was used for meta-analysis. The collected data and codes used for our analysis are provided in the online supplemental materials . …

Development of novel gene signatures for the risk stratification of prognosis and diagnostic prediction of osteosarcoma patients using bioinformatics analysis.

BackgroundOsteosarcoma (OS) is a common malignant bone cancer in children and teenagers that originates from osteoblast cells. Although many biomarkers have been reported in OS, they have not improved the prognosis of this disease. This study sought to identify effective biomarkers for the early diagnosis and prognosis of OS using a comprehensive bioinformatics analysis.MethodsOS-associated microRNAs (miRNAs) were screened in the Human microRNA Disease Database (HMDD). The differentially expressed genes (DEGs) related to OS were screened using 3 data sets (GSE16088, GSE36001, and GSE56001) fro

Совпадение в полном тексте источника
… Statistical analyses were conducted in R version 4.0.4 (The R Foundation for Statistical Computing, Vienna, Austria) and SPSS 22.0 (IBM Corp., Armonk, NY, USA). A P value <0.05 was considered significant. …

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

OBJECTIVE: We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. METHODS: This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv car

Совпадение в полном тексте источника
… (R Foundation for Statistical Computing, Vienna, Austria). Role of the funding source Amgen, the funder of the study, had no role in study design, data collection, data analysis, data interpretation or writing of the manuscript. …

The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000-2015.

BackgroundWe perform an econometric assessment of the impact that pharmaceutical innovation had on the burden of disease in Ireland.MethodsWe use a difference-in-differences (or two-way fixed effects) research design: we investigate whether diseases for which more new drugs were launched had larger subsequent reductions in mortality. This design controls for the effects of general economic and societal factors (e.g. income, education, and behavioral risk factors), to the extent that those effects are similar across diseases.ResultsNew Chemical Entities launched during 1983-1997 are estimated t

Совпадение в полном тексте источника
… First, the number of post-1981 NCEs launched in Ireland during 1982–2015 was more than 12% lower than the number launched in 4 other European countries (Germany, Italy, Austria, and the UK), and Irish patients have access to only 20% of new oncology medicines launched since 2016. 20 Second, utilization …

Management of bone health in patients with cancer: a survey of specialist nurses.

BackgroundPatients with cancer can experience bone metastases and/or cancer treatment-induced bone loss (CTIBL), and the resulting bone complications place burdens on patients and healthcare provision. Management of bone complications is becoming increasingly important as cancer survival rates improve. Advances in specialist oncology nursing practice benefit patients through better management of their bone health, which may improve quality of life and survival.MethodsAn anonymised online quantitative survey asked specialist oncology nurses about factors affecting their provision of support in

Совпадение в полном тексте источника
… Table 1 Demographics, specialties and roles of survey participants DXA , dual energy X-ray absorptiometry Austria ( n = 1), Azerbaijan ( n = 1), Croatia ( n = 1), Cyprus ( n = 1), Denmark ( n = 1), France ( n = 1), Greece ( n = 2), Italy ( n = 1), Malta ( n = 2), Netherlands ( n = 10), Portugal ( n = …

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

BackgroundIxazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients.MethodsNinety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year.ResultsThe overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefi

Совпадение в полном тексте источника
… Ethical approval has been granted from all ethical committees responsible for all participating study sites including the ethical committee of the city of Vienna for Austria, the ethical committee of the medical faculty of Leipzig for Germany, and the central ethics committee of the ministry of health …

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

BACKGROUND: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor progno … , safety, and quality of life. This trial is open for patient enrollment since November 2016 in six Austrian cancer centers. Accrual is planned to be completed within 2 years. DISCUSSION: Based on preclinical and clinical findings an ixazomib and carboplatin combination is thought to be effective in metastatic TNBC patients. The MBC-10 trial is accompani …

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.

Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natural killer (NK) cells can recognize and kill MM cells in vitro and can limit MM growth in vivo. Previous reports have shown that NK cell function is impaired during MM progression and suggested that treatment with immunomodulatory drugs (IMIDs) such as lenalidomide (LEN) could enhance it. However, the effects of IMIDs on NK cells have been tested mostly in vitro or in preclinical models and supporting evidence of their effect in vivo in patients is lacking. Here, we monitored NK cell activity in blo

Совпадение в полном тексте источника
… Vienna, Austria: R Foundation for Statistical Computing; (2015). 21. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. …

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

PurposeTo identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer.Materials and methodsWe pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline clinical and laboratory factors common in both st

Совпадение в полном тексте источника
… This abstract has been presented in part at the 51st Annual Meeting of American Society of Clinical Oncology (Chicago, IL; May 29–June 2, 2015) and at the European Cancer Congress 2015 (Vienna, Austria; September 25–29, 2015). 1 Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M Cancer incidence …

Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study.

Patients with breast cancer and bone metastases often experience skeletal complications (skeletal-related events [SREs]: pathologic fracture, radiation to bone, surgery to bone or spinal cord compression). Prospective data on the health resource burden of SREs are needed for planning healthcare requirements and estimating the value of new treatments, but limited data are available. This prospective, observational study collected health resource utilization (HRU) data independently attributed to SREs by investigators. Eligible patients had bone metastases secondary to breast cancer, life expect

Совпадение в полном тексте источника
… The overall patterns of HRU observed in our study are similar to those reported in studies by Gunther et al. in Austria, the Czech Republic, Poland, Sweden, and Switzerland (Gunther et al. 2011 ), by Felix et al. in Portugal (Felix et al. 2011 ), and by Svendsen et al. in Denmark (Svendsen et al. 2013 …

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… KG, Ingelheim/Germany 15 Boehringer Ingelheim RCV GmbH & Co KG, Vienna/Austria 16 AbbVie Inc., North Chicago/United States of America 17 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield/United States of America/CT Contact E-mail Address: brian.feagan@robartsinc.com Introduction: The IL-23 pathway … Reinisch: Speaker: AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk, Ferring, Immundiagnostik, Mitsubishi, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; Consultant: AbbVie … S. …

Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM2.5, BC, NO2, and O3: An Analysis of European Cohorts in the ELAPSE Project.

INTRODUCTION: Epidemiological cohort studies have consistently found associations between long-term exposure to outdoor air pollution and a … e included in the pooled cohort from existing cohorts in Sweden, Denmark, Germany, the Netherlands, Austria, France, and Italy. Data from the administrative cohorts have been analyzed locally, without transfer to a central database. Privacy regulations prevented transfer of data from administrative cohorts to a central database. More than 28 million adult …

Systematic review of patient-reported outcome item libraries in cancer research: an EORTC Quality of Life Group study.

BackgroundPatient-reported outcome (PRO) item libraries support flexible PRO assessment in cancer research by facilitating the development of customized item lists. However, little is known about the use of item lists in clinical research. This systematic review addresses this by assessing utilization of PRO item libraries and lists in oncology research.MethodsA systematic review of MEDLINE, Embase, and CINAHL identified cancer studies using PRO item libraries to develop item lists, regardless of study design, published between October 2021 and September 2025. Key features of item library usag

Совпадение в полном тексте источника
… Gynecological | Surgery | Symptomatic adverse event tracking | QLQ-C30; QLQ-EN24; Lymphedema QOL tool | EORTC | 7 | Tightness skin legs (1); tightness skin genitals (1); leg pain (1); swelling in genital area (1); swelling in groin (1); sore skin (1); pain in groin (1) Brunner et al. (2023) 60 | Observational (Austria … FACIT | 0 | 1 | 1 FACIT | 0 | 1 | 1 PROMIS | 1 | 0 | 1 Country United States | 18 | 23 | 41 China | 1 | 4 | 5 Japan | 2 | 3 | 5 Australia | 0 | 3 | 3 Denmark | 1 | 2 | 3 Netherlands | 0 | 3 | 3 Belgium | 0 | 2 | 2 Canada | 1 | 1 | 2 Germany | 0 | 2 | 2 Taiwan | 0 | 2 | 2 United Kingdom | 0 | 2 | 2 Austria …

Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia.

Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic/pharmacodynamic target attainment of β-lactams administered in extended infusion versus short 30 min

Совпадение в полном тексте источника
… Presented at: This study was presented at ESCMID Global 2025, Vienna, Austria and SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology) congress 2025, Malaga, Spain. …

Low- and no-calorie sweeteners and beverages and their associated health outcomes: an umbrella review of systematic reviews and meta-analyses.

BackgroundLong-term health effects of low- and no-calorie sweeteners (LNCSs) have not been established.ObjectiveThis review aimed to evaluate the associations between different types of LNCSs and a wide range of health outcomes from observational studies and randomized controlled trials (RCTs).MethodsWe systematically searched PubMed/MEDLINE, Embase, CINAHL, and Google Scholar from inception to December 2024 for meta-analyses. LNCSs were categorized into artificial sweeteners and other non-sugar sweeteners (NSSs), including non-nutritive sweeteners and sugar alcohols, along with their correspo

Совпадение в полном тексте источника
… All statistical analyses were conducted using R software (version 4.3.1; R Foundation for Statistical Computing, Vienna, Austria), with 2-sided P -values < 0.05 considered statistically significant. …

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies. Only 22% would have met eligibility for MagnetisMM-3 cohort A. The overall response rate (ORR) was 65%, including ≥CR in 36%. Median progression-free

Совпадение в полном тексте источника
… Vienna, Austria: R Foundation for Statistical Computing; 2025. 11. …

CD200 является мощным новым фактором роста в Мультимиломе, зависящим от сигнала рецептора IGF1.

CD200 — это иммунный контрольно-пропускной пункт, безошибочно выраженный в 70% недавно диагностированных пациентов с множественной миеломой (ММ) и связанный с плохим исходом. Выражение CD200 клетками опухоли препятствует иммунной реакции через взаимодействие с CD200R и участвует в устойчивости к иммунной терапии. Однако его роль в опухоли остается слабой. В этом исследовании мы показываем, что клетки MM, перевыражающие CD200, представляют собой значительное пролиферативное преимущество в свободных культурных сыворотках, средних и клоногенных анализах. Преимущество роста клеток, опосредованное

Совпадение в полном тексте источника
… In cell growth experiments, recombinant IGF-1 (R&D, Minneapolis, MN USA), recombinant insulin (Roche Diagnostics, Basel, Switzerland) or fetal calf serum (FCS, PAA laboratory GmbH, Linz, Austria) were added on day 0. …

Автологичная трансплантация стволовых клеток гематопоиета стабилизирует атрофию сетчатки в множестве склероза.

Автологическая трансплантация стволовых клеток гематопоиета — это эффективное лечение агрессивных множественных рефракторов склероза для лечения заболеваний. Тем не менее, его воздействие на нейродегенерацию по-прежнему недостаточно изучено, и существует мало прогнозов биомаркеров для клинических результатов после аутологической трансплантации гематопоэтических стволовых клеток. Мы изучили, смягчает ли аутологическая трансплантация стволовых клеток процесс нейродегенерации сетчатки и предвосхищают ли показатели оптической согласованности, полученные на основе сетчатки, развитие инвалидности по

Совпадение в полном тексте источника
… R Foundation for Statistical Computing, Vienna, Austria. 2023. Accessed 4 May 2024. https://www.R-project.org/ 41 Python Software Foundation . Python language reference, version 3.11.2. Accessed 4 May 2024. http://www.python.org 42 Bender R , Lange S . Adjusting for multiple testing–when and how? …